Advanced search×

Transfusion and NHL risk: a meta-answer?

James R Cerhan

Blood 116(16):2863-4 (2010) PMID 20966171

DOI: 10.1182/blood-2010-08-297549
Version: za2963e q8za1 q8zb8 q8zcd q8zd4 q8ze0 q8zf5 q8zgf
Buy PDF

Similar articles you may find interesting…

  1. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leu...
    Antonio F Santidrián, Diana M González-Gironès, ... Joan Gil

    Blood 116(16):3023-32 (2010) PMID 20664053

    We have analyzed the mechanisms involved in AICAR-induced apoptosis in CLL cells in which it activates its only well known molecular target, adenosine monophosphate-activated protein kinase (AMPK). However, AMPK activation with phenformin or A-769662 failed to induce apoptosis in CLL cells and AICAR...
    Buy PDF
  2. A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer Cells
    Sonia A Melo, Catia Moutinho, ... Manel Esteller

    Cancer Cell 18(4):13 (2010) PMID 20951941

    We demonstrate the presence of XPO5-inactivating mutations in a subset of human tumors with microsatellite instability. The XPO5 genetic defect traps pre-miRNAs in the nucleus, reduces miRNA processing, and diminishes miRNA-target inhibition. The XPO5 mutant form lacks a C-terminal region that contr...
    Buy PDF
  3. Validating cancer drug targets.
    John D JD Benson, Ying-Nan P YN Chen, ... Christoph C Lengauer

    Nature 441(7092):451-6 (2006) PMID 16724057

    A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug dis...
    Buy PDF